Analysts Offer Predictions for GlaxoSmithKline plc’s Q1 2019 Earnings (GSK)

Share on StockTwits

GlaxoSmithKline plc (NYSE:GSK) – Research analysts at Jefferies Financial Group lifted their Q1 2019 EPS estimates for shares of GlaxoSmithKline in a note issued to investors on Thursday, March 14th. Jefferies Financial Group analyst P. Welford now anticipates that the pharmaceutical company will earn $0.61 per share for the quarter, up from their previous forecast of $0.60. Jefferies Financial Group has a “Buy” rating and a $45.00 price objective on the stock. Jefferies Financial Group also issued estimates for GlaxoSmithKline’s Q2 2019 earnings at $0.66 EPS, Q3 2019 earnings at $0.92 EPS, Q4 2019 earnings at $0.77 EPS, FY2019 earnings at $2.93 EPS, FY2020 earnings at $3.12 EPS, FY2021 earnings at $3.62 EPS, FY2022 earnings at $3.91 EPS and FY2023 earnings at $4.20 EPS.

GSK has been the topic of several other reports. Zacks Investment Research raised GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a report on Wednesday, November 28th. UBS Group downgraded GlaxoSmithKline from a “buy” rating to a “neutral” rating in a report on Friday, February 22nd. Shore Capital downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Friday, March 8th. BNP Paribas downgraded GlaxoSmithKline from an “outperform” rating to a “neutral” rating in a report on Monday, January 14th. Finally, Exane BNP Paribas downgraded GlaxoSmithKline from an “outperform” rating to a “neutral” rating in a report on Monday, January 14th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $41.99.

GSK stock opened at $40.43 on Friday. GlaxoSmithKline has a 1-year low of $36.13 and a 1-year high of $42.36. The company has a market capitalization of $100.41 billion, a PE ratio of 12.79, a P/E/G ratio of 2.01 and a beta of 0.76. The company has a debt-to-equity ratio of 5.52, a quick ratio of 0.51 and a current ratio of 0.75.

GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings data on Wednesday, February 6th. The pharmaceutical company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.70 by $0.09. GlaxoSmithKline had a return on equity of 160.39% and a net margin of 11.45%. The company had revenue of $10.55 billion for the quarter, compared to analyst estimates of $9.85 billion.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 11th. Stockholders of record on Friday, February 22nd will be issued a $0.597 dividend. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.49. This represents a $2.39 annualized dividend and a dividend yield of 5.91%. The ex-dividend date is Thursday, February 21st. GlaxoSmithKline’s payout ratio is presently 74.68%.

Institutional investors and hedge funds have recently made changes to their positions in the company. Dubuque Bank & Trust Co. lifted its holdings in GlaxoSmithKline by 195.3% during the 4th quarter. Dubuque Bank & Trust Co. now owns 685 shares of the pharmaceutical company’s stock worth $26,000 after buying an additional 453 shares in the last quarter. Claybrook Capital LLC acquired a new position in GlaxoSmithKline during the 4th quarter worth $26,000. Berman Capital Advisors LLC acquired a new position in GlaxoSmithKline during the 4th quarter worth $32,000. 1832 Asset Management L.P. lifted its holdings in GlaxoSmithKline by 35.2% during the 4th quarter. 1832 Asset Management L.P. now owns 967 shares of the pharmaceutical company’s stock worth $37,000 after buying an additional 252 shares in the last quarter. Finally, Lavaca Capital LLC acquired a new position in GlaxoSmithKline during the 4th quarter worth $37,000. 11.07% of the stock is currently owned by institutional investors and hedge funds.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Read More: Book Value Of Equity Per Share – BVPS Explained

Earnings History and Estimates for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Bank of Montreal Can Has $1.67 Million Position in Evolent Health Inc
Bank of Montreal Can Has $1.67 Million Position in Evolent Health Inc
BlackRock Income Trust  Position Lowered by Bank of America Corp DE
BlackRock Income Trust Position Lowered by Bank of America Corp DE
Ballew Advisors Inc Lowers Holdings in iShares Edge MSCI Min Vol USA ETF
Ballew Advisors Inc Lowers Holdings in iShares Edge MSCI Min Vol USA ETF
Bank of America Corp DE Has $527,000 Holdings in La Jolla Pharmaceutical
Bank of America Corp DE Has $527,000 Holdings in La Jolla Pharmaceutical
Ventas  Upgraded by ValuEngine to Buy
Ventas Upgraded by ValuEngine to Buy
Aspiriant LLC Has $600,000 Stake in iShares Core S&P Mid-Cap ETF
Aspiriant LLC Has $600,000 Stake in iShares Core S&P Mid-Cap ETF


© 2006-2019 Ticker Report